This is the first update to the original CTS communication distributed on July 6th. As previously communicated, all CTS healthcare partners will remain on the Grifols ZIKV clinical trial until at least the end of October 2018, which coincides with the end of the WNV season.
Check out the Communication page for the complete details on the NAT ZIKV test update or by clicking the link: Communications
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
Just a reminder that the revised client forms implement today! Don't forget to toss your o...